STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1494-1502

  Wu, Jingjing ^a,b   Lai, Maode ^a   Shao, Changshun ^c   Wang, Jian ^d   Wei, Jian Jun ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Life Sciences Building Rutgers University   (United States)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

HMGA2; Ovarian cancer; STC2

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; HYPOCALCIN; STANNIOCALCIN 2; UNCLASSIFIED DRUG; GLYCOPROTEIN; SIGNAL PEPTIDE; STC2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL COUNT; CELL INVASION; CELL MIGRATION; DISEASE MARKER; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HMGA2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STC2 GENE; SURVIVAL RATE; UPREGULATION; AGED; BIOSYNTHESIS; CANCER STAGING; CELL MOTION; CYSTADENOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HMGA2 PROTEIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 84937231970     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4120     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10: 211-224, 2013.
3. K urman RJ and Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 34: 433-443, 2010.
4. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME: Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6: 2585-2590, 2007.
5. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA and Hampton GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98: 1176-1181, 2001.
6. Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P and Liu J: HMGA2: A potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 34: 18-26, 2010.
7. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J and Wei JJ: HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 71: 349-359, 2011.
8. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123: 348-356, 2008.
9. Wu J and Wei JJ: HMGA2 and high-grade serous ovarian carcinoma. J Mol Med Berl 91: 1155-1165, 2013.
10. Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K: HMGA2 is a driver of tumor metastasis. Cancer Res 73: 4289-4299, 2013.
11. Zha L, Zhang J, Tang W, Zhang N, He M, Guo Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci 58: 724-733, 2013.
12. Serlachius M, Alitalo R, Olsen HS and Andersson LC: Expression of stanniocalcin-1 in megakaryocytes and platelets. Br J Haematol 119: 359-363, 2002.
13. Chang AC and Reddel RR: Identification of a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2. Mol Cell Endocrinol 141: 95-99, 1998.
14. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102: 812-827, 2010.
15. Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H, et al: Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer 125: 926-931, 2009.
16. Girgis AH, Iakovlev VV , Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H, et al: Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 72: 5273-5284, 2012.
17. Yuan Y, Yang ZL, Zou Q, Li JH, Li DQ, Liang LF, Zeng GX and Chen SL: Comparative study of clinicopathological significance, BIRC7, and STC2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Neoplasma 60: 698-705, 2013.
18. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA and Coukos G: Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25: 852-861, 2007.
19. Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 316: 466-476, 2010.
20. McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM and Wei JJ: Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod Pathol 25: 1644-1653, 2012.
21. Cui T and Leng F: Specific recognition of AT-rich DNA sequences by the mammalian high mobility group protein AT-hook 2: A SELEX study. Biochemistry 46: 13059-13066, 2007.
22. B ouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE and Venter DJ: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62: 1289-1295, 2002.
23. Law AY and Wong CK: Stanniocalcin-2 promotes epithelialmesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res 316: 3425-3434, 2010.
24. Yokobori T, Mimori K, Ishii H, Iwatsuki M, Tanaka F, Kamohara Y, Ieta K, Kita Y, Doki Y, Kuwano H, et al: Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol 17: 2601-2607, 2010.
25. Wang YY, Li L, Zhao ZS and Wang HJ: Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol 11: 81, 2013.
26. Volland S, Kugler W, Schweigerer L, Wilting J and Becker J: Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int J Cancer 125: 2049-2057, 2009.
27. Wang H, Wu K, Sun Y, Li Y, Wu M, Qiao Q, Wei Y, Han ZG and Cai B: STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep 45: 629-634, 2012.
28. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, Simon MC and Nathanson KL: Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 72: 112-121, 2012.